csirt@kutim:~/threat-intel/cve/CVE-2026-55084

Katalog CVE

CVSS 8.8 · High EPSS 0,46%

Kerentanan Improper Neutralization of Special Elements used in an SQL Command ('SQL Injection'). Skor CVSS 3.1 8.8 (High) menurut github.com.

Deskripsi (NVD)

DHIS2 is a flexible information system for data capture, management, validation, analytics and visualization. A SQL injection vulnerability was identified in the SqlView API endpoint of the DHIS2 application in the `filter` parameter used by the `/api/sqlViews/{viewId}/data.json` endpoint. An authenticated user with access to a SqlView can inject arbitrary SQL queries inside the `filter` parameter by abusing an expression executed by PostgreSQL and its output is reflected inside the application error message. This behavior enables attackers to extract arbitrary database content using error-based SQL injection. Affected versions include: 2.37, 2.38, 2.39, 2.40.x before 2.40.11.1/2.40.12, 2.41.x before 2.41.8.2, 2.42.x before 2.42.5.1, 2.43.0 before 2.43.0.1, 2.44 development branch before PR #24162 Patched versions include: 2.37-EOS (2026-06-09), 2.38-EOS (2026-06-09), 2.39-EOS (2026-06-09), 2.40.11.1, 2.40.12, 2.41.8.2, 2.42.5.1, 2.43.0.1, 2.44 development branch after PR #24162

Rincian

Terbit di NVD
21 Juli 2026
Terakhir diubah
21 Juli 2026
Status NVD
Deferred
CVSS 3.1
8.8 (High), sumber github.com
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-89: Improper Neutralization of Special Elements used in an SQL Command ('SQL Injection')
EPSS (30 hari)
0,46% peluang dieksploitasi; lebih tinggi dari 37,7% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.